Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect. Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Molnupiravir
Study Locations (20)
California
- Clinica de Salud del Valle de Salinas ( Site 3825) — Castroville
- Ascada Health PC dba Ascada Research ( Site 3750) — Fullerton
- Pacific Clinical Studies ( Site 3827) — Los Alamitos
- Valley Clinical Trials, Inc. ( Site 3707) — Northridge
- FOMAT Medical Research ( Site 3720) — Oxnard
- Paradigm Clinical Research, LLC ( Site 3785) — San Diego
- Optimus Medical ( Site 3817) — San Francisco
- Millennium Clinical Trials ( Site 3758) — Westlake Village
Florida
- Encore Medical Research of Boynton Beach ( Site 3701) — Boynton Beach
- Prestige Clinical Research Center ( Site 3722) — Coral Gables
- Indago Research & Health Center, Inc ( Site 3714) — Hialeah
- Prestige Clinical Research ( Site 3830) — Homestead
- Accel Research Sites Network - St. Pete-Largo Clinical Research Unit ( Site 3779) — Largo
- Clinical Site Partners, LLC dba Flourish Research ( Site 3717) — Leesburg
- Advanced Pulmonary Research Institute ( Site 3781) — Loxahatchee Groves
- Southern Clinical Research ( Site 3773) — Miami
Arizona
- Helios Clinical Research ( Site 3826) — Paradise Valley
- Absolute Clinical Research ( Site 3709) — Phoenix
Alabama
- Cullman Clinical Trials ( Site 3813) — Cullman
Colorado
- Paradigm Clinical Research Centers, Inc ( Site 3718) — Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,082 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2031-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06667700
The ClinicalTrials.gov registry entry for NCT06667700 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,082 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Coronavirus Disease (COVID-19) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06667700 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06667700 about?
NCT06667700 is a clinical study titled "A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)". Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can requir...
What is the current status of trial NCT06667700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,082 participants. The study started on 2024-12-02. Estimated completion is 2031-01-26.
What conditions does trial NCT06667700 study?
This clinical trial studies the following conditions: Coronavirus Disease (COVID-19). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06667700?
The interventions under investigation include: Placebo (DRUG), Molnupiravir (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06667700?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06667700 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.